Table 1.
Differentially expressed genes up- and downregulated in apoptosis.
| Gene | Name | Fold Change CBG 1 µM |
Fold Change CBG 5 µM |
Fold Change CBD 1 µM |
Fold Change CBD 5 µM |
|---|---|---|---|---|---|
| AKT1 | thymoma viral proto-oncogene 1 | 0.80 | 0.74 | 0.84 | 0.96 |
| ATF4 | activating transcription factor 4 | 0.71 | 0.74 | 0.80 | 0.76 |
| BCL2L1 | BCL2-like 1 | 0.97 | 1.20 | 0.96 | 1.29 |
| EIF2AK3 | eukaryotic translation initiation factor 2 alpha kinase 3 | −1.84 | −1.13 | −1.82 | −1.60 |
| ERN1 | endoplasmatic reticulum (ER) to nucleus signaling 1 | −0.91 | −0.91 | −0.71 | −0.84 |
| MAP3K5 | mitogen-activated protein kinase kinase kinase 5 | −1.30 | −0.97 | −0.98 | −0.82 |
| PARP4 | poly(ADP-ribose) polymerase family, member 4 | −1.60 | −1.59 | −1.28 | −1.50 |
| CASP6 | caspase 6 | - | - | - | −3.58 |
| CASP8 | caspase 8 | −1.39 | - | - | −1.81 |
Each gene was associated with the fold change resulting in the analysis of CBG at dose of 1 and 5 µM against CTR-NSC-34 (“Fold Change CBG 1 µM” and “Fold Change CBG 5 µM”) and CBD at dose of 1 and 5 µM (“Fold Change CBD 1 µM” and “Fold Change CBD 5 µM”). The hyphen symbol indicates that the genes do not differ in a statistically significant way compared to CTR-NSC-34.